Inflammatory Bowel Disease

The Art and Science in the Diagnosis and Treatment in 2014

September 12 – 13, 2014
Revere Hotel | Boston Common | Boston MA

IBD14_iconOverview | Agenda | Faculty | Accommodations | Registration
View the printed brochure!

Target Audience

Gastroenterologists, colorectal surgeons, nurses and other healthcare professionals caring for patients with IBD

 

Educational Needs Addressed

Inflammatory Bowel Disease (IBD) is a complex immune-mediated GI disorder which manifests itself commonly as Crohn’s Disease (CD) and ulcerative colitis (UC). A principal focus of research today is in identifying individuals at risk early enough to modify environmental risk factors and to intervene before complications and morbidity become an issue. Precise incidence and prevalence of Crohn’s disease and ulcerative colitis has been limited by a lack of gold standard criteria for diagnosis; inconsistent case ascertainment; and disease misclassification.

Typically, a proper diagnosis often takes months, and conference faculty will address current practice and the need for early diagnosis. Clinical features include fever, abdominal pain, diarrhea, rectal bleeding, weight loss, signs of malnutrition, perianal disease, abdominal mass and, in children and adolescents, growth failure. Endoscopic and colonoscopic examinations are mainstays in diagnosing IBD. Contributing to the difficulty in making the correct diagnosis is the changing phenotypic expression of these diseases. These topics will be discussed at the conference.  Additional topics of great importance for GI practices include understanding the quality measures for the new health care system as well as physicians medico legal responsibilities in caring for patients with IBD.

 

Educational Objectives

At the conclusion of this conference, participants will be able to:

  • Identify the most current approaches to the diagnosis of IBD
  • Describe the best approaches for medical therapy of IBD
  • List the indications and type of surgeries for IBD
  • Recognize the side effects and risks of using immunomodulatory and biologics in the treatment of IBD
  • Identify issues related to pregnancy in IBD

 

Accreditation

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 9.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education Provider Unit Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

In order to receive credit, nurses should attend the sessions and complete an evaluation form. Credit will be awarded commensurate with participation.

This program meets the criteria of the Massachusetts Board of Registration in Medicine for risk management study. (0.5 credits)



Support

This conference is supported in part by exhibit fees from:

  • Abbvie
  • Forest Pharmaceuticals
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs LLC.
  • Takeda Pharmaceuticals U.S.A., Inc.
  • UCB

This conference is supported in part by educational grants from:

  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs LLC.
  • Prometheus Laboratories Inc.
  • Salix Pharmaceuticals Inc.
  • Shire
  • Takeda Pharmaceuticals International, Inc., U.S. Region
  • UCB




Core Competencies

This activity has been developed with consideration given to the American Board of Medical Specialties Six Core Competencies. This activity will increase your competency in the areas of medical knowledge, practice-based learning and improvement, interpersonal and communication skills and systems-based practice.

Dietary Considerations and Special Services

The CME staff will work to accommodate dietary requests (including, but not limited to: vegetarian, kosher, and low-sodium menus) received in writing at least one week prior to the conference. To request reasonable accommodations for a disability, please notify the Boston University CME Office, in writing, at least two weeks prior to the start of the conference.

Disclosure Policy

It is the policy of Boston University School of Medicine Department of Continuing Medical Education, that faculty disclose to program participants any real or apparent conflict of interest. In addition, the faculty is asked to disclose any discussion pertaining to the unapproved use of pharmaceuticals and devices. Complete disclosure information will be available on site in the printed course materials.

Substitution/Cancellation Policy

Substitutions may be made at any time without an additional charge. Refunds, less an $50 administrative fee, will be issued for all cancellations received two weeks prior to the start of the conference. Should cancellation occur within the two-week window, a credit will be issued, not a refund. Credits will be honored for up to two years. “No shows” are subject to the full course fee. Cancellations/substitution(s) must be made in writing. Refunds or credits will not be issued once the conference has started. This course is subject to change or cancellation.

 

Education program is endorsed by:
Crohn’s and Colitis Foundation of America
CCFA



Education program is provided by:

Boston University School of Medicine Continuing Medical Education

In conjuction with:
Beth Israel Deaconess Medical Center
Boston Medical Center
Brigham and Women’s Hospital
Boston Children’s Hospital
Massachusetts General Hospital
Tufts Medical Center
UMass Memorial Medical Center

 

BUSM CME Facebook BUSM CME Twitter